Paper39588561
Targeting CDK7 Enhances the Antitumor Efficacy of Enzalutamide in Androgen Receptor-Positive Triple-Negative Breast Cancer by Inhibiting c-MYC-mediated Tumorigenesis.
Xie X and 9 others. Mol Cancer Ther, 2025. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Targeting CDK7 Enhances the Antitumor Efficacy of Enzalutamide in Androgen Receptor-Positive Triple-Negative Breast Cancer by Inhibiting c-MYC-mediated Tumorigenesis. Papers, record 39588561. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39588561
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Targeting CDK7 Enhances the Antitumor Efficacy of Enzalutamide in Androgen Receptor-Positive Triple-Negative Breast Cancer by Inhibiting c-MYC-mediated Tumorigenesis.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Triple Negative Breast Neoplasms | Major topic |
| Phenylthiohydantoin | Major topic |
| Receptors, Androgen | Major topic |
| Proto-Oncogene Proteins c-myc | Major topic |
| Cyclin-Dependent Kinases | Major topic |
| Humans | |
| Benzamides | |
| Nitriles | |
| Animals | |
| Female | |
| Mice | |
| Cell Line, Tumor | |
| Xenograft Model Antitumor Assays | |
| Cyclin-Dependent Kinase-Activating Kinase | |
| Cell Proliferation | |
| Drug Synergism | |
| Gene Expression Regulation, Neoplastic | |
| Carcinogenesis |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA016672 | NCI NIH HHS | United States | P30CA016672 | PubMed and NIH | NIH RePORTER |
| CA016672-29 | Center for Cancer Research (CCR) | PubMed | PubMed | ||
| P30 CA054174 | NCI NIH HHS | United States | P30CA054174 | PubMed and NIH | NIH RePORTER |
| P30 CA071789 | NCI NIH HHS | United States | P30CA071789 | PubMed and NIH | NIH RePORTER |
| P30CA016672 | Center for Cancer Research (CCR) | P30CA016672 | PubMed and NIH | NIH RePORTER | |
| APR-18-006 | Breast Cancer Research Foundation (BCRF) | PubMed | PubMed |
References59
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18511414 | Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer. | J Biol Chem | 2008 | https://conductscience.org/library/papers/18511414 | PubMed |
| 2 | 32650419 | Mechanisms of Androgen Receptor Agonist- and Antagonist-Mediated Cellular Senescence in Prostate Cancer. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32650419 | PubMed |
| 3 | 31466944 | CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation. | Cancer Discov | 2019 | https://conductscience.org/library/papers/31466944 | PubMed |
| 4 | 32988969 | A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer. | Clin Cancer Res | 2020 | https://conductscience.org/library/papers/32988969 | PubMed |
| 5 | 23965901 | Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. | Clin Cancer Res | 2013 | https://conductscience.org/library/papers/23965901 | PubMed |
| 6 | 23010705 | Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast carcinoma. | Am J Clin Pathol | 2012 | https://conductscience.org/library/papers/23010705 | PubMed |
| 7 | 37076563 | The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer. | Br J Cancer | 2023 | https://conductscience.org/library/papers/37076563 | PubMed |
| 8 | 21552212 | Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. | Mod Pathol | 2011 | https://conductscience.org/library/papers/21552212 | PubMed |
| 9 | 29883487 | Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features. | PLoS One | 2018 | https://conductscience.org/library/papers/29883487 | PubMed |
| 10 | 25693131 | The Mediator complex: a central integrator of transcription. | Nat Rev Mol Cell Biol | 2015 | https://conductscience.org/library/papers/25693131 | PubMed |
| 11 | 28144231 | Non-Genomic Actions of the Androgen Receptor in Prostate Cancer. | Front Endocrinol (Lausanne) | 2017 | https://conductscience.org/library/papers/28144231 | PubMed |
| 12 | 23634260 | The CDK Network: Linking Cycles of Cell Division and Gene Expression. | Genes Cancer | 2012 | https://conductscience.org/library/papers/23634260 | PubMed |
| 13 | 36975020 | A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022). | Expert Opin Ther Pat | 2023 | https://conductscience.org/library/papers/36975020 | PubMed |
| 14 | 25512207 | Targeting heat shock proteins in metastatic castration-resistant prostate cancer. | Nat Rev Urol | 2015 | https://conductscience.org/library/papers/25512207 | PubMed |
| 15 | 33384381 | Using biochemistry and biophysics to extinguish androgen receptor signaling in prostate cancer. | J Biol Chem | 2021 | https://conductscience.org/library/papers/33384381 | PubMed |
| 16 | 23031358 | Expression of androgen receptors in triple negative breast carcinomas. | Acta Histochem | 2013 | https://conductscience.org/library/papers/23031358 | PubMed |
| 17 | 18507821 | Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. | BMC Cancer | 2008 | https://conductscience.org/library/papers/18507821 | PubMed |
| 18 | 29340907 | Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer. | Horm Cancer | 2018 | https://conductscience.org/library/papers/29340907 | PubMed |
| 19 | 26201402 | Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease. | Horm Cancer | 2015 | https://conductscience.org/library/papers/26201402 | PubMed |
| 20 | 34754128 | Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. | Nat Rev Clin Oncol | 2022 | https://conductscience.org/library/papers/34754128 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42278564 | Beyond Molecular Classification in Metastatic Triple-Negative Breast Cancer: Toward Subtype-Guided Precision Oncology. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42278564 | PubMed |
| 41986659 | ATR inhibition potentiates the antitumor efficacy of HER3-DXd in HER3-positive/HR-positive breast cancer by increasing DNA damage. | Br J Cancer | 2026 | https://conductscience.org/library/papers/41986659 | PubMed |
| 41968987 | Integrative multi-omic analysis identified ERBB2 mutations and senescence-driven immune suppression as dual therapeutic targets in LAR triple-negative breast cancer. | Cancer Biol Med | 2026 | https://conductscience.org/library/papers/41968987 | PubMed |
| 40897935 | Advances of androgen receptor in triple-negative breast cancer: from molecular mechanisms to clinical applications. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40897935 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AR | 367 | PubTator's text mining | https://conductscience.org/library/genes/367 | NCBI Gene |
| CDK7 | 1022 | PubTator's text mining | https://conductscience.org/library/genes/1022 | NCBI Gene |
| MYC | 4609 | PubTator's text mining | https://conductscience.org/library/genes/4609 | NCBI Gene |
| PTPRF | 5792 | PubTator's text mining | https://conductscience.org/library/genes/5792 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39588561
GET https://conductscience.org/api/papers/v1/39588561/references?page=2